- Home
- SQFT vs CMND Comparison
SQFT vs CMND Comparison
Compare SQFT & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | CMND |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.6M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SQFT | CMND |
|---|---|---|
| Price | $1.42 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.2K | ★ 68.8K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,814,708.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.32 | $0.07 |
| 52 Week High | $10.47 | $4.66 |
Technical Indicators
Market Signals| Indicator | SQFT | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 21.69 | 55.02 |
| Support Level | $1.32 | $1.74 |
| Resistance Level | $3.09 | $2.25 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 6.60 | 54.65 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.